does this product just convert to plain 100% DHT? what are the effects on hairline and is there anything you can use to reduce it but more importantly and what i'd worry about how does it effect your prostate?
If you are prone to MPB- you really can't use any type of PH or AAS w/o repurcussions- with the exception of nandrolone, b/c it converts to DHN. Doesn't matter what you take- DHT analogs, test, anything you can think of that is not nandrolone, converts to DHT by the time it reaches the scalp, at least to some extent. The number of DHT receptors in the scalp is genetically predetermined- so if you are prone to MPB, and use AAS or PH, you may speed things up quite a bit. The One isn't worse than anything else out there in terms of shedding- in fact,
no shedding was reported by any of the testers.
I guess your next question would be "Can I just use a DHT blocker?" Not a good idea- you can pretty much kiss a lot of the strength and performance gains from your cycle goodbye- DHT is the dominant androgen in the CNS- testosterone is actually a prohormone to DHT in the CNS, and by blocking it, you block the mechanism that is in part for muscle firing and recruitment.
As for the prostate- no worries- the latest studies to come out point to DHT actually being safer than testosterone for TRT, b/c many of the deleterious effects on the prostate previously attributed to DHT are actually from aromatization of testosterone to estrogen- take a look:J Clin Endocrinol Metab. 2002 Apr;87(4):1467-72.Click here to read Links
Comment in:
J Clin Endocrinol Metab. 2002 Apr;87(4):1462-6.
The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study.
Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS.
Division of Urology, Department of Surgery, University of Oulu, FIN-90014 Oulu, Finland.
The objective of the study was to investigate the effects of dihydrotestosterone (DHT) gel on general well-being, sexual function, and the prostate in aging men. A total of 120 men participated in this randomized, placebo-controlled study (60 DHT and 60 placebo). All subjects had nocturnal penile tumescence once per week or less, andropause symptoms, and a serum T level of 15 nmol/liter or less and/or a serum SHBG level greater than 30 nmol/liter. The mean age was 58 yr (range, 50-70 yr). Of these subjects, 114 men completed the study. DHT was administered transdermally for 6 months, and the dose varied from 125-250 mg/d. General well-being symptoms and sexual function were evaluated using a questionnaire, and prostate symptoms were evaluated using the International Prostate Symptoms Score, transrectal ultrasonography, and assay of serum prostate-specific antigen. Early morning erections improved transiently in the DHT group at 3 months of treatment (P < 0.003), and the ability to maintain erection improved in the DHT group compared with the placebo group (P < 0.04). No significant changes were observed in general well-being between the placebo and the DHT group. Serum concentrations of LH, FSH, E2, T, and SHBG decreased significantly during DHT treatment. Treatment with DHT did not affect liver function or the lipid profile. Hemoglobin concentrations increased from 146.0 +/- 8.2 to 154.8 +/- 11.4 g/liter, and hematocrit from 43.5 +/- 2.5% to 45.8 +/- 3.4% (P < 0.001). Prostate weight and prostate-specific antigen levels did not change during the treatment. No major adverse events were observed. Transdermal administration of DHT improves sexual function and may be a useful alternative for androgen replacement. As estrogens are thought to play a role in the pathogenesis of prostate hyperplasia, DHT may be beneficial, compared with aromatizing androgens, in the treatment of aging men.